← 返回

基于多组学生物信息学分析的食管鳞状细胞癌琥珀酰化相关预后模型的构建与验证

英文原题:Development and validation of a succinylation-related prognostic model for esophageal squamous cell carcinoma based on multi-omics bioinformatics analysis.

查看英文原题

Development and validation of a succinylation-related prognostic model for esophageal squamous cell carcinoma based on multi-omics bioinformatics analysis.

PubMed 2026/02/17(内容时间) Hereditas Q2 · IF 2.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

一种新型的七基因琥珀酰化相关特征被建立并验证为 ESCC 的独立预后生物标志物。该特征捕捉了高风险肿瘤的免疫抑制特征,并可能为个体化治疗策略提供基础。

研究思路结论见上方概要

食管鳞状细胞癌(ESCC)是一种侵袭性强、预后差的恶性肿瘤,亟需可靠的预后生物标志物。蛋白质琥珀酰化是一种与肿瘤生物学相关的关键翻译后修饰,但其在ESCC中的预后意义尚未得到系统研究。

本研究分析了来自GSE53624(n = 119)和癌症基因组图谱(TCGA)-ESCC(n = 95)队列的转录组数据。通过加权基因共表达网络分析(WGCNA)、精选的SRG集和差异表达分析,鉴定了琥珀酰化相关基因(SRGs)。使用LASSO Cox回归构建了预后特征,并进行了内部和外部验证。通过CIBERSORT/ssGSEA评估了免疫浸润。评估了miRNA-mRNA和蛋白质-蛋白质相互作用(PPIs)以及药物敏感性。通过单细胞RNA测序(scRNA-seq)确认了基因定位。

共鉴定出41个与ESCC相关的高置信度SRGs。建立了一个稳健的七基因预后特征(IGFBP3、CMA1、FN1、CTSG、TIMP1、MBL2和SP5)。在训练队列(GSE53624,P < 0.001)和验证队列(TCGA,P = 0.026)中,被分为高风险组和低风险组的患者总生存期(OS)存在显著差异。风险评分仍是一个独立预后因素,并被纳入预测列线图。高风险肿瘤以免疫抑制性肿瘤微环境(TME)为特征,表现为嗜酸性粒细胞和自然杀伤(NK)细胞浸润减少以及单核细胞丰度增加。此外,特征基因与多种抗癌药物的耐药性相关。scRNA-seq分析显示,这些基因主要在恶性细胞、成纤维细胞和髓系细胞中表达。

展开英文摘要原文

Esophageal squamous cell carcinoma (ESCC), an aggressive malignancy with poor prognosis, requires reliable prognostic biomarkers. Protein succinylation, a critical post-translational modification implicated in cancer biology, has not yet been systematically investigated for its prognostic significance in ESCC.

Transcriptomic data from GSE53624 (n = 119) and The Cancer Genome Atlas (TCGA)-ESCC (n = 95) cohorts were analyzed in this study. Succinylation-related genes (SRGs) were identified via weighted gene co-expression network analysis (WGCNA), a curated SRG set, and differential expression analysis. A prognostic signature was constructed using LASSO Cox regression and validated internally and externally. Immune infiltration was assessed by CIBERSORT/ssGSEA. miRNA-mRNA and protein-protein interactions (PPIs) and drug sensitivity were evaluated. Gene localization was confirmed with single-cell RNA sequencing (scRNA-seq).

41 high-confidence SRGs associated with ESCC were identified. A robust seven-gene prognostic signature (IGFBP3, CMA1, FN1, CTSG, TIMP1, MBL2, and SP5) was established. Patients stratified into high- and low-risk groups exhibited significantly different overall survival (OS) in both the training cohort (GSE53624, P < 0.001) and the validation cohort (TCGA, P = 0.026). The risk score remained an independent prognostic factor and was incorporated into a predictive nomogram. High-risk tumors were characterized by an immunosuppressive tumor microenvironment (TME), with reduced eosinophil and natural killer (NK) cell infiltration and increased monocyte abundance. In addition, signature genes were associated with resistance to multiple anticancer agents. scRNA-seq analysis revealed predominant expression of these genes in malignant cells, fibroblasts, and myeloid cells.

A novel seven-gene succinylation-related signature was established and validated as an independent prognostic biomarker for ESCC. This signature captures immunosuppressive features of high-risk tumors and may provide a foundation for individualized therapeutic strategies.

论文信息

作者
Hua B、Wang W、Huang H、Chang X、Ye T
第一作者单位
Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, Yining, Xinjiang, China.China
通讯作者单位
Department of Thoracic Surgery, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, No. 92, Stalin Street, Yining City, Xinjiang Uygur Autonomous Region, 835000, China. yetao811216@163.com.China
期刊
Hereditas2026 Feb 17
原文标识
PubMed 41703614 · DOI 10.1186/s41065-026-00653-2